Investor Relations
Elevating the treatment of cancer
Join us to build a future in which each patient has access to the right physicians, the right tests, and the right therapeutics to treat their individual tumor.
Corporate Overview
Elevation Oncology is founded on the belief that every patient living with cancer deserves to know what is driving the growth of their disease and have access to therapeutics that can stop it. We aim to make genomic tests actionable by selectively developing drugs to inhibit the specific alterations that have been identified as drivers of tumor growth.
Together with our peers, we work towards a future in which each tumor’s unique genomic test result can be matched with a purpose-built precision medicine to enable an individualized treatment plan for each patient. Our lead candidate, seribantumab, is intended to inhibit tumor growth driven by NRG1 fusions and is currently being clinically tested in the Phase 2 CRESTONE study for patients with tumors of any origin that have an NRG1 fusion.
Details on CRESTONE are available at www.NRG1fusion.com. For more information visit www.ElevationOncology.com.
Stock Information
Change
Volume
Market Cap
Stock Information
NASDAQELEV
Latest news & updates
Sign Up For Alerts
Investor updates
Sign up for our investor mailing list below to receive the have the latest news and financials from Elevation Oncology delivered to your inbox.
Analyst Coverage
| Bank | Analyst |
| Cowen Inc. | Mark Alan Frahm Ph.D. |
| H.C. Wainwright & Co. | Michael G. King Jr. |
| J.P. Morgan | Anupam Rama |
| SVB Leerink | Andrew Scott Berens M.D. |
| Wedbush Securities | Robert Driscoll Ph.D. |